Novo Nordisk(US:NVO) Jin Rong Jie·2026-02-04 01:52Core Viewpoint - Novo Nordisk reported a strong financial performance for 2025, with significant sales growth driven by its GLP-1 products, particularly the semaglutide line, which includes both diabetes and weight management medications [1] Financial Performance - Total sales for Novo Nordisk reached 309.1 billion Danish kroner, reflecting a 10% increase when adjusted for constant currency [1] - Sales of the semaglutide product line amounted to 228.288 billion Danish kroner [1] Product Sales Breakdown - Ozempic (diabetes version of semaglutide) generated sales of 127.089 billion Danish kroner [1] - Wegovy (weight management version of semaglutide) achieved sales of 79.106 billion Danish kroner [1] - Oral semaglutide tablets (Novo Nordisk's diabetes treatment) recorded sales of 22.093 billion Danish kroner [1] - Wegovy tablets, launched in the U.S. on January 5, have seen a total weekly prescription volume of approximately 50,000 [1] Regulatory Developments - Novo Nordisk has submitted a supplemental new drug application to the FDA for the 7.2 mg version of the weight management semaglutide injection [1] - The company is also anticipating approval results for new therapies, including Mim8 for hemophilia treatment and CagriSema for obesity treatment [1] Market Position - Novo Nordisk holds a leading position in the GLP-1 market and insulin market for diabetes treatment in China, while maintaining high growth in the obesity and rare disease markets [1]